Y Intercept Hong Kong Ltd Takes $10.06 Million Position in Intuitive Surgical, Inc. $ISRG

Y Intercept Hong Kong Ltd purchased a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,487 shares of the medical equipment provider’s stock, valued at approximately $10,057,000.

Several other institutional investors and hedge funds also recently bought and sold shares of ISRG. Norges Bank bought a new stake in Intuitive Surgical during the 2nd quarter valued at $2,569,260,000. Rakuten Investment Management Inc. purchased a new position in shares of Intuitive Surgical during the third quarter valued at $388,436,000. Vanguard Group Inc. raised its holdings in shares of Intuitive Surgical by 2.1% in the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock valued at $18,115,025,000 after acquiring an additional 670,302 shares in the last quarter. Jennison Associates LLC lifted its stake in Intuitive Surgical by 20.4% in the second quarter. Jennison Associates LLC now owns 3,122,390 shares of the medical equipment provider’s stock worth $1,696,738,000 after acquiring an additional 528,359 shares during the period. Finally, Bessemer Group Inc. grew its holdings in Intuitive Surgical by 89.3% during the 2nd quarter. Bessemer Group Inc. now owns 788,328 shares of the medical equipment provider’s stock worth $428,386,000 after acquiring an additional 371,806 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ISRG shares. The Goldman Sachs Group restated a “buy” rating and issued a $714.00 price target on shares of Intuitive Surgical in a report on Friday, January 9th. Rothschild & Co Redburn raised their price objective on Intuitive Surgical from $610.00 to $615.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Intuitive Surgical in a report on Monday, December 29th. Royal Bank Of Canada raised their price target on shares of Intuitive Surgical from $625.00 to $650.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Intuitive Surgical in a research report on Thursday, January 15th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average target price of $617.57.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q4 results beat Wall Street: Revenue and adjusted EPS topped estimates, backed by higher procedure volumes and system demand — a primary near‑term driver of recurring instrument sales. Reuters: Intuitive Surgical beats quarterly estimates on demand for surgical robots
• Positive Sentiment: Analysts boost some targets and reaffirm conviction: Bernstein raised its target sharply (big upside), Raymond James and BTIG reaffirmed/outperform with higher targets — supporting upside potential from elongation of the company’s growth runway. Benzinga: Analysts revise forecasts after Q4
• Neutral Sentiment: Guidance is measured: Management expects mid‑teens da Vinci procedure growth (midpoint ~14%) and 2026 gross margin around 67–68%, while flagging higher operating expenses for R&D — signaling steady growth but potential margin/operating‑leverage moderation. MarketBeat: Intuitive Surgical Just Proved the Growth Engine Still Runs
• Neutral Sentiment: JURA clinical update and milestone PRs add long‑term optionality: Early imaging data from the JURA feasibility study and a new 20 million‑patient da Vinci milestone reinforce long‑term growth narratives beyond core platforms. TipRanks: JURA feasibility study update GlobeNewswire: 20 Million Patients Benefit from da Vinci Surgery
• Negative Sentiment: Tariffs and gross‑margin pressure noted: Management expects tariffs to cut gross margins (about a 1.2% headwind in 2026) and flagged some gross‑margin decline vs. recent quarters — a medium‑term profitability risk. Zacks: Q4 beat but gross margin declines
• Negative Sentiment: Mixed analyst moves and a few downgrades: Some firms trimmed targets or moved to in‑line/hold (Evercore, Zacks), creating near‑term debate over valuation vs. growth and muting upside for traders focused on short‑term catalysts. The Fly: Evercore lowers price target

Insider Transactions at Intuitive Surgical

In related news, insider Gary S. Guthart sold 22,806 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $570.89, for a total value of $13,019,717.34. Following the sale, the insider owned 2,694 shares in the company, valued at $1,537,977.66. This represents a 89.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Brian Edward Miller sold 3,500 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $575.00, for a total transaction of $2,012,500.00. Following the completion of the transaction, the executive vice president owned 5,758 shares in the company, valued at approximately $3,310,850. This trade represents a 37.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 55,714 shares of company stock valued at $31,617,799. 0.70% of the stock is owned by company insiders.

Intuitive Surgical Trading Down 0.3%

NASDAQ:ISRG opened at $523.99 on Friday. The company has a market capitalization of $187.84 billion, a P/E ratio of 66.41, a PEG ratio of 4.28 and a beta of 1.67. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $609.08. The firm has a fifty day simple moving average of $562.32 and a 200-day simple moving average of $511.79.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.26. The company had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. Intuitive Surgical had a return on equity of 15.18% and a net margin of 28.38%.The firm’s quarterly revenue was up 18.8% on a year-over-year basis. During the same quarter last year, the business posted $2.21 EPS. Equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.